Sarcoidosis: an enigmatic disease calls for a measured workup.
Biopsy; Radiography; Physical Examination; Tomography; X-Ray Computed; Thoracic; Disease Remission; Heart-Lung Transplantation; Sarcoidosis – Complications; Adrenal Cortex Hormones – Therapeutic Use; Sarcoidosis – Therapy; Adrenal Cortex Hormones – Adverse Effects; Sarcoidosis – Diagnosis; Sarcoidosis – Pathology; Sarcoidosis – Radiography; Sarcoidosis – Surgery
Treatment options for sarcoidosis range from observation to complex immunosuppressive agents and organ transplant. A careful examination will help you assess the likelihood of spontaneous remission and determine when to initiate appropriate treatment to forestall organ damage.
Barreiro TJ; DeMarco R; Gemmel D J; Schaub C R
Patient Care for the Nurse Practitioner
2005
2005-10
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Inhaled corticosteroid use in asthmatic children receiving Ohio Medicaid: trend analysis, 1997-2001.
Female; Male; Ohio; Child; Infant; United States; Sex Factors; Human; Cross Sectional Studies; Adolescence; Retrospective Design; Regression; Preschool; Newborn; Administration; Inhalation; Ambulatory Care – Statistics and Numerical Data; Emergency Service – Statistics and Numerical Data; Blacks – Statistics and Numerical Data; Whites – Statistics and Numerical Data; Medicaid – Statistics and Numerical Data; Hospitalization – Statistics and Numerical Data; Adrenal Cortex Hormones – Therapeutic Use; Adrenal Cortex Hormones – Administration and Dosage; Asthma – Diagnosis; Asthma – Drug Therapy; Asthma – Ethnology; Drug Utilization – Statistics and Numerical Data; Drug Utilization – Trends
BACKGROUND: In 1997, national guidelines emphasized that inhaled corticosteroids (ICSs) are key therapy for individuals with all classes of persistent asthma, including children. OBJECTIVE: To examine the effect of these guidelines via time-trend analysis of ICS dispensation among children with asthma and Ohio Medicaid insurance. METHODS: A retrospective cross-sectional analysis by yearly cohorts was performed. From January 1, 1997, to December 31, 2001, all children from birth to the age of 18 years with 6 months of Ohio Medicaid enrollment or more, 1 or more asthma diagnoses associated with a provider claim, and 1 or more prescription claims for an asthma medication in a given calendar year were identified using claims data. The daily beclomethasone equivalent (BME) dose, the daily albuterol equivalent dose, and asthma-related health care use were calculated for each child within each yearly cohort. A time-trend regression analysis of subjects enrolled in all 5 years examined factors associated with BME. RESULTS: A total of 77,557 children met the study criteria. Among the 1,475 children enrolled during all 5 years, year of enrollment was a positive independent predictor of BME after adjustment for age, race, sex, systemic steroid bursts, albuterol equivalent dose, and health care use (P \textless .001). CONCLUSIONS: The daily BME dose significantly increased for children with asthma insured by Ohio Medicaid from 1997 to 2001. However, the percentages of children receiving both ICS and a therapeutic BME dose were alarmingly low. The mean BME dose was particularly low among children with 1 or more emergency department visits, no hospitalizations, and 3 or fewer physician visits for asthma per year, suggesting that broader efforts to target this group are needed.
Stevenson MD; Heaton PC; Moomaw CJ; Bean JA; Ruddy RM
Annals of Allergy, Asthma & Immunology
2008
2008-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/s1081-1206(10)60049-x" target="_blank" rel="noreferrer noopener">10.1016/s1081-1206(10)60049-x</a>
Managing psoriasis: What's best for your patient?
Male; Ultraviolet Therapy; Combined Modality Therapy; Patient Compliance; Photochemotherapy; Middle Age; Administration; Transcutaneous; Adrenal Cortex Hormones – Therapeutic Use; Antiinflammatory Agents – Therapeutic Use; Dermatologic Agents – Therapeutic Use; Immunosuppressive Agents – Therapeutic Use; Psoriasis – Drug Therapy; Psoriasis – Radiotherapy; Psoriasis – Therapy
Uhlenhake EE; Mehregan DA
Journal of Family Practice
2012
2012-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).